메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

쭐랄롱꼰대학교, 모근 과학의 혁신 AnthoRice™ Complex 공개

[ 메디채널 황정호 기자 ] 방콕, 2026년 2월 18일 -- 쭐랄롱꼰 대학교와 마히돌 대학교가 유기농 라이스베리 쌀에서 유래한 태국 개발 모근 케어 혁신 기술 AnthoRice™ Complex의 상용화를 위한 획기적인 기술이전 협력에 착수했으며, 이는 학술 연구 성과를 실제 건강 및 웰니스 분야에 적용하는 중요한 전환점으로 평가된다. 쭐랄롱꼰 대학교 약학대학 연구진이 개발한 AnthoRice™ Complex는 유기농 라이스베리 쌀 추출물과 StemAktiv® 기술을 결합한 제품이다. 해당 연구는 국제 학술지에서 검증받았으며, 2026년 초 시리랏 병원(Siriraj Hospital)에서 임상시험에 착수할 예정이다. 이에 따라 본 제품은 일반 화장품에서 코스메슈티컬로의 나아갈 수 있는 가능성을 모색하고 있다. 양 대학의 리더들은 이번 협력이 대학을 사회적 가치 창출의 핵심 동력으로 삼겠다는 공동 비전을 반영한다고 강조했다. 협약 체결식에서는 쭐라 파테크(Chula PharTech Co., Ltd.)와 타이톤부리 코퍼레이션(Thaithonburi Corporation Co., Ltd.) 간 기술이전 계약이
- 황정호 기자
- 2026-02-18 10:00
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate. Telix has been preparing the European and U.S. regulatory packages for TLX101-Px concurrently, bringing forward the European submission to meet an agreed filing date while aligning with aspects of the U.S. Food and Drug Administration (FDA) pac
- 김갑성 기자
- 2026-02-18 05:54
New Guidelines from NCCN Detail Fundamental Differences in Cancer in Children Compared to Adults

National Comprehensive Cancer Network publishes new guidelines for Pediatric Soft Tissue Sarcomas, focused on rhabdomyosarcoma. PLYMOUTH MEETING, Pa., Feb. 18, 2026 -- The National Comprehensive Cancer Network® (NCCN®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Soft Tissue Sarcomas. This is the 7th NCCN Guidelines® for a pediatric cancer, expanding the overall library to cover 91 topics in cancer care. The guidelines present the latest evidence-based, expert consensus-driven recommendations for nearly every
- 김갑성 기자
- 2026-02-18 00:47
FDA 510(k) Clearance Establishes Broad Intended Use for Copan's PhenoMATRIX®, Expanding Clinical Microbiology Capabilities

MURRIETA, Calif., Feb. 17, 2026 -- Copan Group announced today that PhenoMATRIX®, its automated image assessment software used with WASPLab® full laboratory automation, received FDA 510(k) clearance as a Class II device in the United States. PhenoMATRIX is an in vitro diagnostic software that uses artificial intelligence with laboratory-defined rules and clinical information to automatically sort images of bacterial culture plates, helping laboratory professionals streamline plate review while maintaining expert oversight. The cleared intended use include
- 김갑성 기자
- 2026-02-17 23:00
코판의 PhenoMATRIX®, FDA 510(k) 승인으로 광범위한 사용 목적 확립 및 임상 미생물학 역량 확대

무리에타, 캘리포니아, 2026년 2월 17일 -- 2월 17일 코판 그룹(Copan Group)이 자사의 전면 검사실 자동화 솔루션인 WASPLab®과 함께 사용되는 자동 이미지 판독 소프트웨어 PhenoMATRIX®가 미국에서 2등급 의료기기로 FDA 510(k) 승인을 획득했다고 발표했다. PhenoMATRIX는 인공지능(AI)과 검사실에서 정의한 규칙 및 임상 정보를 결합해 세균 배양 플레이트 이미지를 자동으로 분류하는 체외 진단 소프트웨어로, 검사실 전문가는 이 소프트웨어를 활용해 전문적 감독을 유지하면서 효율적으로 플레이트를 판독할 수 있다. 이번에 승인된 사용 목적에는 혈액 한천, 초콜릿 한천, 맥콘키 한천(MacConkey agar) 및 CHROMagar orientation 배양 배지 플레이트가 포함된다. 이를 통해 미생물 성장 감지, 집락 수 추정, 표현형 집락 특성에 따른 분리균 감별을 통해 반정량적 및 정성적 이미지 기반 분석을 수행할 수 있다. 코판 다이애그노스틱스(Copan Diagnostics)의 파브리치오 마조키(Fabrizio Mazzocchi)
- 김갑성 기자
- 2026-02-17 23:00
BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

XI'AN, China, Feb. 17, 2026 -- Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech Co., Ltd., and Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co.,
- 김갑성 기자
- 2026-02-17 22:00
Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity

Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers—Delivering Risk Prediction Where Proteomics Falls Short MORRISVILLE, N.C., Feb. 17, 2026 -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced its industry-leading global metabolomics platform was used by researchers from Kite, a Gilead company, for the most extensive metabolomic study ever conducted in the context of CAR T-cell therapy. Leverag
- 김갑성 기자
- 2026-02-17 22:00
Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage

Headlines: Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1 Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights. 2 Reduces solvent consumption by up to 4× versus 2.1 mm I.D. columns, helping laboratories meet sustainability goals, lower operating costs, and accelerate time to results withou
- 김갑성 기자
- 2026-02-17 21:00
sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization

[ 메디채널 김갑성 기자 ] Amai Proteins announces a major milestone for sweelin® in the U.S. market. The U.S. FDA has completed its review of the GRAS (Generally Recognized as Safe) notice for sweelin® and confirmed it has no safety concerns regarding the use of sweelin® as a general sweetener. The GRAS Notice was submitted just nine months ago, reflecting the strength and quality of Amai Protein's comprehensive safety dossier. sweelin® is a next-generation sweet protein that enables significant sugar reduction and replaces conventional sweeteners with a protein-based alternativ
- 김갑성 기자
- 2026-02-17 20:13
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026. Co-PSMA IIT evaluated the performance of Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care (SOC) 68Ga-PSMA-11 in 50 patients with biochemical recurrence (BCR) of prostate cancer (with prostate-specific antigen [PSA] 0.2-0.7
- 김갑성 기자
- 2026-02-16 22:03

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 02일 23시 00분